PRIME
At
baseline:
baseline:
29% of patients
had
an IGA PN-S
score
of 4 (over 100
nodules)1,2,a
71% of patients
had an IGA PN-S
score
of 3 (20-100
nodules)1,2
At
Week 24:
Week 24:
48% of
DUPIXENT
patients
improved to an
IGA PN-S score
of 0 or 1 (5
nodules or fewer)
compared to 18%
with placebo1,2
Illustrative representation of nodule clearance based on clinical trial results.
Actual individual results may vary.
IGA PN-S ranges from 0 (clear) to 1 (almost clear), 2 (mild), 3 (moderate), and 4 (severe).
- In PRIME2, 38% of patients had 100 or more nodules at baseline, with 45% of all DUPIXENT patients achieving 5 nodules or fewer at Week 24 vs 16% with placebo.2
aAll study participants had 20-100 nodules upon screening and at Day 1 (inclusion criteria).
IGA PN-S, Investigator's Global Assessment PN‑Stage.
Dosage and Administration
Thinking about prescribing DUPIXENT? Find the information you need to get started.